| Q35446580 | A bioartificial liver device secreting interleukin-1 receptor antagonist for the treatment of hepatic failure in rats |
| Q35805123 | A new technique for primary hepatocyte expansion in vitro |
| Q34503111 | A preliminary study for constructing a bioartificial liver device with induced pluripotent stem cell-derived hepatocytes. |
| Q37527804 | A tryptophan derivative, ITE, enhances liver cell metabolic functions in vitro |
| Q28246028 | AASLD position paper: the management of acute liver failure |
| Q33939738 | Acute hepatic failure: a Western perspective |
| Q24680190 | Acute liver failure |
| Q79337582 | Acute liver failure |
| Q44851733 | Acute liver failure. Current aspects of diagnosis and therapy |
| Q34095674 | Acute liver failure: established and putative hepatitis viruses and therapeutic implications |
| Q33870232 | Acute liver failure: targeted artificial and hepatocyte-based support of liver regeneration and reversal of multiorgan failure |
| Q38066726 | Advances in cell sources of hepatocytes for bioartificial liver |
| Q35129274 | Artificial Liver Support in the Third Millennium |
| Q28237883 | Artificial and bioartificial liver support |
| Q41991763 | Artificial and bioartificial liver support systems for acute and acute-on-chronic hepatic failure: A meta-analysis and meta-regression |
| Q24247462 | Artificial and bioartificial support systems for liver failure |
| Q34975989 | Artificial and bioartificial support systems for liver failure: a Cochrane Hepato-Biliary Group Protocol. |
| Q36449252 | Artificial liver support at present and in the future |
| Q33949286 | Artificial liver support devices for fulminant liver failure |
| Q38481056 | Artificial liver support with the molecular adsorbent recirculating system: activation of coagulation and bleeding complications. |
| Q53359972 | Auxiliary partial orthotopic liver transplantation for acute liver failure. |
| Q37084233 | Bioartificial Therapy of Sepsis: Changes of Norepinephrine-Dosage in Patients and Influence on Dynamic and Cell Based Liver Tests during Extracorporeal Treatments |
| Q35071892 | Bioartificial liver support anno 2001. |
| Q41515091 | Bioartificial liver support for fulminant hepatic failure. |
| Q92323574 | Bioartificial liver support systems for acute liver failure: A systematic review and meta-analysis of the clinical and preclinical literature |
| Q37202810 | Bioartificial liver systems: why, what, whither? |
| Q34079017 | Bioartificial organ support for hepatic, renal, and hematologic failure |
| Q36603041 | Bioengineering the liver: scale-up and cool chain delivery of the liver cell biomass for clinical targeting in a bioartificial liver support system. |
| Q73690856 | Blood coagulation in anhepatic pigs: effects of treatment with the AMC-bioartificial liver |
| Q27001113 | Cell sources, liver support systems and liver tissue engineering: alternatives to liver transplantation |
| Q53155879 | Cell therapeutic options in liver diseases: cell types, medical devices and regulatory issues. |
| Q37964633 | Cell therapies for liver diseases |
| Q35781240 | Cellular therapies for liver replacement |
| Q36929640 | Cellular therapy and bioartificial approaches to liver replacement |
| Q24540124 | Clinical application of bioartificial liver support systems |
| Q59798396 | Comparison of extracorporeal cellular therapy (ELAD) vs standard of care in a randomized controlled clinical trial in treating Chinese subjects with acute-on-chronic liver failure |
| Q38820033 | Concise Review: Liver Regenerative Medicine: From Hepatocyte Transplantation to Bioartificial Livers and Bioengineered Grafts |
| Q51798256 | Convective Flow Through a Hollow Fiber Bioartificial Liver |
| Q45204277 | Cryopreservation of isolated primary rat hepatocytes: enhanced survival and long-term hepatospecific function. |
| Q34170330 | Current status of liver support systems |
| Q43600142 | Development and characterization of a hybrid bioartificial liver using primary hepatocytes entrapped in a basement membrane matrix |
| Q40171126 | Double-compartment cell culture apparatus: construction and biochemical evaluation for bioartificial liver support. |
| Q40655709 | Efficacy of a Polyurethane Foam/Spheroid Artificial Liver by Using Human Hepatoblastoma Cell Line (Hep G2) |
| Q42168257 | Efficacy of an extracorporeal flat-plate bioartificial liver in treating fulminant hepatic failure |
| Q45160784 | Efficacy of double-filtration plasmapheretic cross-circulation with a high-permeability membrane using canine harvested liver in porcine fulminant hepatic failure model |
| Q43585973 | Efficacy of nonwoven fabric bioreactor immobilized with porcine hepatocytes for ex vivo xenogeneic perfusion treatment of liver failure in dogs |
| Q52979953 | Enzyme release in hybrid liver support systems: marker for quality prior to clinical application. |
| Q50051348 | Establishment and characterization of an immortalized human hepatocyte line for the development of bioartificial liver system |
| Q40006841 | Establishment of immortalized human hepatocytes by introduction of HPV16 E6/E7 and hTERT as cell sources for liver cell-based therapy |
| Q35046537 | Etiology and management of fulminant hepatic failure. |
| Q30559330 | Evaluation of a novel bioartificial liver in rats with complete liver ischemia: treatment efficacy and species-specific alpha-GST detection to monitor hepatocyte viability |
| Q34719069 | Evaluation of the Hepa Wash® treatment in pigs with acute liver failure |
| Q37993562 | Extracorporeal bioartificial liver for treating acute liver diseases. |
| Q37846058 | Extracorporeal liver support |
| Q38055288 | Extracorporeal liver support |
| Q38702799 | Extracorporeal liver support devices for listed patients |
| Q90550033 | Extracorporeal liver support in patients with liver failure: a systematic review and meta-analysis of randomized trials |
| Q33345664 | Extracorporeal liver support with molecular adsorbents recirculating system in patients with severe acute alcoholic hepatitis |
| Q40875080 | Extracorporeal liver support: cell-based therapy for the failing liver |
| Q30854712 | Extracorporeal perfusion for the treatment of acute liver failure |
| Q33731099 | Extracorporeal support and hepatocyte transplantation in acute liver failure and cirrhosis |
| Q38740963 | Extracorporeal support for patients with acute and acute on chronic liver failure |
| Q33343084 | First clinical use of a novel bioartificial liver support system (BLSS). |
| Q41377300 | Fluidized-bed bioartificial liver assist devices (BLADs) based on microencapsulated primary porcine hepatocytes have risk of porcine endogenous retroviruses transmission |
| Q38210263 | From in vitro to in situ tissue engineering |
| Q33540212 | Fulminant hepatic failure |
| Q73571416 | Fulminant hepatic failure |
| Q81544318 | Fulminant hepatic failure |
| Q35184553 | Fulminant liver disease |
| Q90705143 | Functional Analysis of Human Hepatocytes Isolated From Chimeric Mouse Liver |
| Q40507204 | Functional activity of human hepatoma cells transfected with adenovirus-mediated hepatocyte nuclear factor (HNF)-4 gene |
| Q58829232 | Functional evaluation of the AMC-BAL to be employed in a multicentric clinical trial for acute liver failure |
| Q83232569 | Hepatic assist devices: will they ever be successful? |
| Q35781251 | Hepatic tissue engineering |
| Q35578597 | Hepatocyte hollow-fibre bioreactors: design, set-up, validation and applications |
| Q40225550 | Hepatotoxicity of Antimycotics Used for Invasive Fungal Infections: In Vitro Results. |
| Q36492605 | How regenerative medicine and tissue engineering may complement the available armamentarium in gastroenterology? |
| Q37579509 | Human Hepatic HepaRG Cells Maintain an Organotypic Phenotype with High Intrinsic CYP450 Activity/Metabolism and Significantly Outperform Standard HepG2/C3A Cells for Pharmaceutical and Therapeutic Applications |
| Q91972725 | Human hepatocellular adenoma as a promising cell source for bioartificial liver systems |
| Q38901747 | Immortalization of Human Fetal Hepatocyte by Ectopic Expression of Human Telomerase Reverse Transcriptase, Human Papilloma Virus (E7) and Simian Virus 40 Large T (SV40 T) Antigen Towards Bioartificial Liver Support |
| Q55472665 | Impaired Cell Viability and Functionality of Hepatocytes After Incubation With Septic Plasma—Results of a Second Prospective Biosensor Study. |
| Q39389129 | Impaired cell functions of hepatocytes incubated with plasma of septic patients |
| Q36559990 | Improved survival of porcine acute liver failure by a bioartificial liver device implanted with induced human functional hepatocytes |
| Q35018059 | Improving the next generation of bioartificial liver devices |
| Q45160787 | In vitro evaluation of cross-circulation system using semipermeable membrane combined with whole liver perfusion |
| Q42485953 | In-depth physiological characterization of primary human hepatocytes in a 3D hollow-fiber bioreactor. |
| Q34027980 | Is there a future for liver-assist devices? |
| Q38016613 | Key challenges to the development of extracorporeal bioartificial liver support systems |
| Q46603807 | Laparoscopy-assisted creation of a liver failure model in pigs. |
| Q35617373 | Large animal models of fulminant hepatic failure in artificial and bioartificial liver support research |
| Q38960582 | Liver Cell Culture Devices |
| Q44583417 | Liver micro-organs transcribe albumin and clotting factors and increase survival of 92% hepatectomized rats |
| Q44609373 | Liver support in acute liver failure |
| Q38156043 | Liver support strategies: cutting-edge technologies |
| Q38080028 | Liver support systems: will they ever reach prime time? |
| Q38089346 | Liver tissue engineering and cell sources: issues and challenges |
| Q43808445 | Long-term expression of highly differentiated functions by isolated porcine hepatocytes perfused in a radial-flow bioreactor. |
| Q37571437 | Management of acute liver failure |
| Q38482166 | Molecular adsorbent recirculating system in liver transplantation: Safety and efficacy. |
| Q51449625 | Novel bioartificial liver support system: preclinical evaluation. |
| Q37997980 | Organ repair and regeneration: an overview. |
| Q33692600 | Overview of extracorporeal liver support systems and clinical results |
| Q52078620 | Oxygen transfer in a diffusion-limited hollow fiber bioartificial liver. |
| Q55449029 | Paracetamol hepatotoxicity: how to prevent. |
| Q41460579 | Paracetamol-induced acute liver failure: prevention and management |
| Q37424698 | Pig liver xenotransplantation as a bridge to allotransplantation: which patients might benefit? |
| Q74267311 | Polyurethane membrane as an efficient immobilization carrier for high-density culture of rat hepatocytes in the fixed-bed reactor |
| Q44135487 | Preclinical evaluation of the Excorp Medical, Inc, Bioartificial Liver Support System |
| Q42413876 | Present and Future Developments in Hepatic Tissue Engineering for Liver Support Systems : State of the art and future developments of hepatic cell culture techniques for the use in liver support systems |
| Q38014905 | Proliferative human cell sources applied as biocomponent in bioartificial livers: a review |
| Q34313335 | Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure. |
| Q35596562 | Prospects for extracorporeal liver support |
| Q51369567 | Radial flow bioreactor outperforms hollow-fiber modules as a perfusing culture system for primary porcine hepatocytes. |
| Q50937798 | Regenerative medicine: an insight. |
| Q33762458 | Review article: liver support systems in acute hepatic failure |
| Q40851415 | Review article: the management of acute liver failure |
| Q37148553 | Selecting Cells for Bioartificial Liver Devices and the Importance of a 3D Culture Environment: A Functional Comparison between the HepaRG and C3A Cell Lines |
| Q51092437 | Significant survival prolongation in pigs with fulminant hepatic failure treated with a novel microgravity-based bioartificial liver. |
| Q51032622 | Stem Cell Therapies for Treatment of Liver Disease. |
| Q35706287 | Systematic review: extracorporeal bio-artificial liver-support system for liver failure |
| Q36304257 | Technology insight: liver support systems |
| Q39789530 | Telomerase activity and hepatic functions of rat embryonic liver progenitor cell in nanoscaffold-coated model bioreactor |
| Q47831420 | The Pharmabiotic Approach to Treat Hyperammonemia. |
| Q40171140 | The significant improvement of survival times and pathological parameters by bioartificial liver with recombinant HepG2 in porcine liver failure model |
| Q33652334 | Three-dimensional culture of human embryonic stem cell derived hepatic endoderm and its role in bioartificial liver construction |
| Q89509450 | Tissue Engineering in Liver Regenerative Medicine: Insights into Novel Translational Technologies |
| Q37955184 | Use of the molecular adsorbent recirculating system (MARS™) for the management of acute poisoning with or without liver failure |
| Q77087308 | What progress with artificial livers? |
| Q93140593 | When to use renal replacement therapy and bioartificial support for renal failure in patients with cirrhosis |
| Q36355331 | Which are the right cells to be used in a bioartificial liver? |
| Q34881789 | Xenogeneic bioartificial liver support: where are we now? |
| Q73925431 | [Acute liver failure] |
| Q77053073 | [Artificial liver, where are we?] |
| Q88019229 | [Extracorporeal therapies in hepatic diseases] |
| Q75198763 | [Liver replacement therapy. Reliable indications in acute liver failure] |